Radiofrequency Ablation in Breast Cancer
Primary Purpose
Breast Cancer
Status
Terminated
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Radiofrequency ablation
Sponsored by

About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring Ablation Technique, Breast cancer, Stage 1, Lumpectomy
Eligibility Criteria
Inclusion Criteria:
- Breast single tumor,
- Clearly visible by ultrasound,
- Diameter < 2 cm
- Located >1 cm from the chest wall and skin;
- Ductal carcinoma according to previous biopsy,
- < 20% of intraductal carcinoma
Exclusion Criteria:
- Breast cancer in men;
- Personal history of ipsilateral breast cancer;
- Age <40 years;
- Pregnancy or breastfeeding;
- Suspicion of intraductal extension or multifocality by mammography or MRI;
- Tumour not visible by ultrasound;
- Diameter > 2 cm;
- Distance to muscle or skin <1 cm;
- Lobular carcinoma;
- Intraductal carcinoma in > 20% of the biopsy sample
- Patients undergoing neoadjuvant chemotherapy or hormonotherapy.
Sites / Locations
- Hospital Universitario Bellvitge
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
RFA group
Control group
Arm Description
A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.
Normal excision of the tumor according to the protocol
Outcomes
Primary Outcome Measures
Intraoperative free margins (distance between the tumor and the margin in order to indicate if extensions are mandatory.)
The pathologist performed a macroscopic study of the specimen, measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory.
Secondary Outcome Measures
Security of RFA (Adverse effects and cosmetic result)
Adverse effects and cosmetic result will be evaluated 15 days after the procedure
Efficacy of RFA (Tumoral viability in the ablation zone)
Tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunel
Full Information
NCT ID
NCT02281812
First Posted
October 30, 2014
Last Updated
May 31, 2018
Sponsor
Hospital Universitari de Bellvitge
1. Study Identification
Unique Protocol Identification Number
NCT02281812
Brief Title
Radiofrequency Ablation in Breast Cancer
Official Title
Impact of Radiofrequency Ablation on Surgical Margins in Early Stage of Malignant Breast Tumors
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Terminated
Why Stopped
Increased local adverse effect (breast inflamation and infection)
Study Start Date
September 2013 (undefined)
Primary Completion Date
July 2017 (Actual)
Study Completion Date
July 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital Universitari de Bellvitge
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Background/Main objective: Radiofrequency ablation (RFA) is a minimally invasive procedure widespread accepted in the treatment of different tumors, especially in the liver but its benefit is not yet well-known in breast cancer.
Our main objective is to evaluate the usefulness of RFA in < 2cm malignant breast tumors to reduce the proportion of positive margins.
Methodology: The investigator propose a single-center, single-blind, phase I and II randomized controlled trial. Phase I:Security of the cool-tip cluster electrode assessing the potential adverse effects in three stages: initial,intermediate and final. Phase II: Randomized clinical trial, 2 parallel groups with 37 patients in each one.
Experimental group: percutaneous RFA previous to conventional lumpectomy. Control group: conventional surgery with lumpectomy. The number of positive margins in both groups, and the need of extending margin resection will be assessed intraoperatively. Inclusion criteria: women >40 years, infiltrating ductal breast carcinoma by biopsy. The tumor must be unique, visible by ultrasound, smaller than 2cm and located > 1 cm from the chest wall and the skin. Patients will be followed up for a period of two years to assess cosmetic result, short -term and long -term complications and recurrences.
Expected results: The "cool-tip" (cluster) ablation method reduces by at least 30% the risk of intraoperative extensions for positive margins during lumpectomy compared to conventional surgery in breast tumors with a diameter < 2 cm.
Therefore this procedure may reduce the risk of second surgeries and the removed volume of tissue.Consequently the final cosmetic result should be improved.
Detailed Description
Main objectives of the project:
To evaluate the usefulness of radiofrequency ablation (RFA) to achieve a lower percentage of positive margins.
To validate clinically the efficacy and safety of the method in breast tumors smaller than < 2 cm.
Specific objectives of the project:
To demonstrate that , after RFA, clear margins are increased in the intraoperative pathological analysis compared to conventional surgery.
To quantify the number of positive margins requiring intraoperative extension in each patient, comparing the ratio in both groups.
To quantify the percentage of patients requiring intraoperative extension compared in both groups.
To demonstrate a reduction in the volume of breast tissue removed after RFA compared to conventional surgery.
Comparing in both groups the anteroposterior, transverse and craniocaudal diameters of the excised specimen, measured in cm, and to calculate the volume.
Tumor weight in grams (including extensions) will be measured to compare the weights in both groups.
To evaluate the differences in cosmetic outcome after RFA versus conventional surgery.
a. An international scale will be used and the scores will be compared. There will be two independent assessments, one for the physician and another for the patient.
To demonstrate the effectiveness of the RFA by cluster "cool-tip" electrode in the experimental group.
RFA is considered as complete when no viable tumor tissue is evidenced by oxidation-reduction reaction mediated by NADH-diaphorase after surgical resection. Mitochondrial dysfunction will be also evaluated by semiquantitative and quantitative method using the enzyme cytochrome c oxidase or Complex IV (COX) and tunel. Any residual viable tumor tissue will be considered as incomplete RFA.
Risk factors for incomplete ablations will be analyzed, especially tumor vascularization.
To demonstrate the safety of RFA by cluster "cool-tip" electrode in breast cancer tumors a. To quantify all side effects that may occur after the RFA and / or surgery and to correlate the complication rate in each group with severity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
Ablation Technique, Breast cancer, Stage 1, Lumpectomy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
RFA group
Arm Type
Experimental
Arm Description
A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Normal excision of the tumor according to the protocol
Intervention Type
Procedure
Intervention Name(s)
Radiofrequency ablation
Intervention Description
After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
Primary Outcome Measure Information:
Title
Intraoperative free margins (distance between the tumor and the margin in order to indicate if extensions are mandatory.)
Description
The pathologist performed a macroscopic study of the specimen, measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory.
Time Frame
1 hour
Secondary Outcome Measure Information:
Title
Security of RFA (Adverse effects and cosmetic result)
Description
Adverse effects and cosmetic result will be evaluated 15 days after the procedure
Time Frame
15 days
Title
Efficacy of RFA (Tumoral viability in the ablation zone)
Description
Tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunel
Time Frame
7 days
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Breast single tumor,
Clearly visible by ultrasound,
Diameter < 2 cm
Located >1 cm from the chest wall and skin;
Ductal carcinoma according to previous biopsy,
< 20% of intraductal carcinoma
Exclusion Criteria:
Breast cancer in men;
Personal history of ipsilateral breast cancer;
Age <40 years;
Pregnancy or breastfeeding;
Suspicion of intraductal extension or multifocality by mammography or MRI;
Tumour not visible by ultrasound;
Diameter > 2 cm;
Distance to muscle or skin <1 cm;
Lobular carcinoma;
Intraductal carcinoma in > 20% of the biopsy sample
Patients undergoing neoadjuvant chemotherapy or hormonotherapy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amparo Garcia-Tejedor, MDPhD
Organizational Affiliation
Hospital Universitario Bellvitge-Idibell_Universidad de Barcelona
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitario Bellvitge
City
Hospitalet de Llobregat
State/Province
Barcelona
ZIP/Postal Code
08908
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30129904
Citation
Garcia-Tejedor A, Guma A, Soler T, Valdivieso A, Petit A, Contreras N, Chappuis CG, Falo C, Pernas S, Amselem A, Pla MJ, Fernandez-Montoli E, Burdio F, Ponce J. Radiofrequency Ablation Followed by Surgical Excision versus Lumpectomy for Early Stage Breast Cancer: A Randomized Phase II Clinical Trial. Radiology. 2018 Nov;289(2):317-324. doi: 10.1148/radiol.2018180235. Epub 2018 Aug 21.
Results Reference
derived
Learn more about this trial
Radiofrequency Ablation in Breast Cancer
We'll reach out to this number within 24 hrs